A phase Ⅰ/Ⅱ clinical trial of three dimensional conformal radiation therapy combined with transcatheter arterial chemoembolization for liver cancer
- VernacularTitle:肝癌介入治疗和三维适形放疗的临床Ⅰ/Ⅱ期试验
- Author:
Shixiong LIANG
;
Guoliang JIANG
;
Zhenhua ZHOU
- Publication Type:Journal Article
- Keywords:
liver neoplasms;
radiotherapy;
three dimensional conformal radiation therapy;
trancatheter arterial chemoembolization
- From:China Oncology
1998;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To investigate the toxicities and res po nse of liver cancers to 3-dimensional conformal radiation therapy (3-DCRT) com bined with Trancatheter arterial chemoembolization (TACE) Methods :The histopathological confirmed liver cancer patients were treated by 3-DCRT co mbined with TACE, all patients received TACE before 3-DCRT The total irradiati on dose is 50 Gy to 58 Gy in daily fractions of 2 Gy Each planning target volu me (PTV) received a minimum of 90% of the prescribed dose Each mean liver dose not reached 30 Gy, V 30 Gy (the percentage of normal liver volume with ra diation dose≥30 Gy) less than 33% Results:Thirty patients were included in this study including 2 1 hepatocellular carcinoma Survivals at 1 year after 3-DCRT were 76%, with a median survival time of 8 months 2 patients developed Grade 1 acute liver toxi city and one patient experienced Grade 2 gastrointestinal complications No pat ient developed Grade 2 or greater liver toxicity Conclusions:The use of 3-DCRT technique for liver cancer is a safe and efficient method O ur experience indicated the total irradiation dose above 58 Gy is feasible in da ily fractions of 2 Gy, if the mean liver dose did not reach 30 Gy and V 30 G y
